Drug Trial Radar · NCT05023486
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
121
Actual
Start
Dec 7, 2021
Primary completion
Jun 30, 2026
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Novita Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of continuously dosed NP-G2-044 monotherapy and NP-G2-044 in combination with anti-PD-1 therapy.
Conditions
- Advanced or Metastatic Solid Tumor Malignancies
Interventions
NP-G2-044 MonotherapyDrug
1600 mg QD, 2000mg QD, and 2100 mg QD
Anti-PD-1 TherapyDrug
previously initiated per standard of care, at a dose and frequency in accordance with the package insert
NP-G2-044 Combination therapyDrug
1600 mg QD or 2100 mg QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Identification of the NP-G2-044 Monotherapy Recommended Phase 2 Dose (RP2D)Time frame: 6 months
- Number of incidences of Treatment Emergent Adverse Events with NP-G2-044 monotherapyTime frame: Time of first dose of any study drug(s) until 30 days after the last dose of study drug(s)
- NP-G2-044 anti-tumor preliminary efficacy signals when administered as continuously dosed monotherapy assessed by RECIST 1.1Time frame: 24 months
- Identification of the RP2D for patients receiving NP-G2-044 in combination with anti-PD-1 therapyTime frame: 9 months
- Number of incidences of Treatment Emergent Adverse Events with NP-G2-044 and anti-PD-1 combination therapyTime frame: Time of first dose of any study drug(s) until 30 days after the last dose of study drug(s)
- NP-G2-044 anti-tumor preliminary efficacy signals when administered in combination with anti-PD-1 therapy assessed by RECIST 1.1Time frame: 24 months
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Honor Health Research Institute
Scottsdale, Arizona
University of Arizona - Cancer Center
Tucson, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
City of Hope
Duarte, California
City of Hope Irvine Lennar
Irvine, California
Hoag Memorial Hospital Presbyterian - Gynecologic Oncology Associates
Newport Beach, California
Nuvance Health
Norwalk, Connecticut
University of Florida (UF) - Shands Cancer Center
Gainesville, Florida
Indiana University (IU) Melvin and Bren Simon Cancer Center
Indianapolis, Indiana
University of Kansas Cancer Center
Fairway, Kansas
Henry Ford Health System
Detroit, Michigan
Atlantic Health System - Morristown Medical Center
Morristown, New Jersey
University of Cincinnati (UC) - Cancer Institute
Cincinnati, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
University of Texas Southwestern
Dallas, Texas
Virginia Cancer Specialists
Fairfax, Virginia
Virginia Commonwealth University - Massey Cancer Center
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.